See what happened at SABCS 2023  Learn more

Clinical Evidence for Node-Positive Patients

It’s never been as clear which node-positive patients can safely be spared chemotherapy.1-7
RxPONDER Trial | SWOG-8814 Study

RxPONDER trial: expanding groundbreaking benefits to node-positive patients

The RxPONDER trial (A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer) prospectively randomized 5,083 HR+, HER2-, node-positive patients with Recurrence Score® (RS) results 0-25 to receive chemotherapy followed by endocrine therapy or endocrine therapy alone. The trial objectives were to8:

  • Assess the chemotherapy benefit for these patients according to their Recurrence Score result
  • Determine if the Oncotype DX® test predicts recurrence and guides treatment decisions
Graphic RxPONDER Trial Design

Most HR+, HER2-, N1, postmenopausal patients can be spared chemotherapy

Key findings from the study, led by the independent Southwest Oncology Group (SWOG) Cancer Research Network and sponsored by the National Cancer Institute (NCI), indicate that9:

  • Patients with low Recurrence Score results can safely forgo chemotherapy without compromising survival rates
  • Postmenopausal women with 1 to 3 positive nodes and Recurrence Score results 0-25 can forgo adjuvant chemotherapy regardless of clinical pathological parameters
  • Premenopausal women with 1 to 3 positive nodes and Recurrence Score results 0-25 modestly benefit from chemotherapy

Safely spare postmenopausal patients from chemotherapy with confidence9

Postmenopausal women with Recurrence Score results 0-25 did not show benefit of chemotherapy in addition to endocrine therapy (competing risk-adjusted HR=1.12, 95% CI 0.82-1.52, P=0.49). Consistent lack of chemotherapy benefit was observed for invasive disease-free survival (IDFS) for subgroups of age, tumor size, grade, Recurrence Score result, and number of positive lymph nodes.



Graphic N1 Postmenopausal Chart

 

Determine chemotherapy options for N1 premenopausal patients with precision10

Premenopausal women with Recurrence Score results 0-25 had a significant benefit in disease recurrence-free interval (DRFI) from the addition of chemotherapy to endocrine therapy (competing risk-adjusted HR=0.64, 95% CI 0.43-0.95, P=0.026). Consistent benefit of chemotherapy was observed for IDFS for subgroups of age, tumor size, Recurrence Score result, and number of positive lymph nodes. The 5-year absolute benefit of chemotherapy for distant recurrence was 2.4% (RS 0-13: 2.3%; RS 14-25: 2.8%).

Graphic N1 Premenopausal Chart

This 21-gene test is categorized by the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) as “preferred” among gene expression assays for prognosis and prediction of chemotherapy benefit11

  • Recommend to “strongly consider” for postmenopausal N1, HR+, HER2- patients with early-stage breast cancer who are candidates for chemotherapy (category 1 recommendation)
  • Also to be considered for premenopausal N1, HR+, HER2- patients with early-stage breast cancer who are candidates for chemotherapy

The only test recognized by major guidelines for its high quality of evidence and robust strength of recommendation12-17

  • Strongly recommended for N1 postmenopausal patients with ER+, HER2- early-stage breast cancer

SWOG-8814 study

The SWOG-8814 study was performed on a cohort of 1,477 eligible postmenopausal patients with ER+, node-positive breast cancer.18 The likelihood of the Recurrence Score result to predict chemotherapy benefit was analyzed in 367 patients.3

Results from the study, led by the independent SWOG Cancer Research Network, indicate that:

  • Recurrence Score result accurately predicts chemotherapy benefit in node-positive patients3
  • There is no benefit to chemotherapy for those with low Recurrence Score results3
  • There is a strong benefit to chemotherapy for high Recurrence Score results3
Graphic Recurrence Score® results 0-17 chart
Graphic Recurrence Score® results 18-30 chart
Graphic Recurrence Score® results 31-100 chart

Icon doctor

Use our online physician portal

Order tests, access results, receive updates, and more in one place.

Sign up now